Aratana Therapeutics, Inc. (PETX) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
11400 TOMAHAWK CREEK PARKWAY, SUITE 340 LEAWOOD, KS 66211 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2019 MRQ | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 42,671 | 67,615 | 88,303 | 86,202 | 98,072 | 45,754 | |||
| Cash and cash equivalents | 41,431 | 66,868 | 87,307 | 26,755 | 9,823 | 41,084 | |||
| Short-term investments | 1,240 | 747 | 996 | 59,447 | 88,249 | 4,670 | |||
| Receivables | 2,204 | 2,406 | 87 | 60 | 352 | ||||
| Inventory, net of allowances, customer advances and progress billings | 11,425 | 13,576 | 11,130 | 1,306 | 427 | 55 | |||
| Inventory | 11,425 | 13,576 | 11,130 | 1,306 | 427 | 55 | |||
| Deferred costs | 76 | 20 | 189 | ||||||
| Other undisclosed current assets | 1,827 | 1,566 | 2,002 | 1,262 | 1,058 | 2,656 | |||
| Total current assets: | 58,127 | 85,239 | 101,542 | 89,019 | 99,909 | 48,465 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 693 | 1,166 | 1,948 | 2,555 | 620 | 98 | |||
| Long-term investments and receivables | 2,452 | ||||||||
| Long-term investments | 2,452 | ||||||||
| Intangible assets, net (including goodwill) | 46,945 | 47,911 | 47,021 | 54,848 | 103,721 | 66,936 | |||
| Goodwill | 40,846 | 41,295 | 39,382 | 39,781 | 41,398 | 20,796 | |||
| Intangible assets, net (excluding goodwill) | 6,099 | 6,616 | 7,639 | 15,067 | 62,323 | 46,140 | |||
| Restricted cash and investments | 351 | 350 | 350 | 350 | |||||
| Other noncurrent assets | 320 | 526 | 545 | 294 | 1,201 | 37 | |||
| Total noncurrent assets: | 48,309 | 49,953 | 49,864 | 58,047 | 107,994 | 67,071 | |||
| TOTAL ASSETS: | 106,436 | 135,192 | 151,406 | 147,066 | 207,903 | 115,536 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 5,412 | 11,163 | 13,263 | 5,647 | 6,819 | 5,819 | |||
| Interest and dividends payable | 41 | ||||||||
| Employee-related liabilities | 2,587 | 2,017 | 1,017 | ||||||
| Accounts payable | 911 | 7,451 | 7,436 | 1,400 | 1,532 | 2,307 | |||
| Accrued liabilities | 1,914 | 3,712 | 5,827 | 4,247 | 3,229 | 2,495 | |||
| Debt | 17,333 | 14,413 | 8,625 | ||||||
| Business combination, contingent consideration, liability | 4,248 | ✕ | |||||||
| Deferred revenue and credits | ✕ | ✕ | 800 | ||||||
| Deferred tax liabilities | 413 | ||||||||
| Other liabilities | 12 | 37 | 46 | 57 | |||||
| Other undisclosed current liabilities | 145 | 7,000 | 7,000 | (2,058) | 1,600 | ||||
| Total current liabilities: | 5,557 | 35,496 | 34,688 | 5,684 | 9,468 | 16,901 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 19,492 | 25,775 | 39,710 | 14,963 | 9,310 | ||||
| Long-term debt, excluding current maturities | 19,492 | 25,775 | 39,710 | 14,963 | 9,310 | ||||
| Liabilities, other than long-term debt | 57 | 70 | 540 | 122 | 1,640 | 1,741 | |||
| Deferred tax liabilities, net | 1,610 | 1,666 | |||||||
| Other liabilities | 57 | 70 | 540 | 122 | 30 | 75 | |||
| Other undisclosed noncurrent liabilities | 1,543 | ||||||||
| Total noncurrent liabilities: | 57 | 19,562 | 26,315 | 39,832 | 16,603 | 12,594 | |||
| Total liabilities: | 5,614 | 55,058 | 61,003 | 45,516 | 26,071 | 29,495 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 100,822 | 80,134 | 90,403 | 101,550 | 181,832 | 86,041 | |||
| Common stock | 48 | 43 | 37 | 35 | 34 | 23 | |||
| Treasury stock, value | (1,175) | (1,107) | (1,088) | (1,088) | (1,081) | ||||
| Additional paid in capital | 350,745 | 321,599 | 286,909 | 263,941 | 254,993 | 112,515 | |||
| Accumulated other comprehensive loss | (7,558) | (7,085) | (9,862) | (9,320) | (4,150) | ||||
| Accumulated deficit | (241,238) | (233,316) | (185,593) | (152,018) | (67,964) | ||||
| Other undisclosed equity, attributable to parent | (26,497) | ||||||||
| Total equity: | 100,822 | 80,134 | 90,403 | 101,550 | 181,832 | 86,041 | |||
| TOTAL LIABILITIES AND EQUITY: | 106,436 | 135,192 | 151,406 | 147,066 | 207,903 | 115,536 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 35,412 | 25,573 | 38,551 | 678 | 767 | 123 | ||
| Revenue, net | ✕ | ✕ | 25,573 | 38,551 | 678 | 767 | 123 | |
| Cost of revenue | (7,800) | (16,737) | (3,518) | (1,909) | (2,337) | (108) | ||
| Cost of goods and services sold | (6,783) | (16,387) | (3,139) | (365) | (333) | (108) | ||
| Gross profit: | 27,612 | 8,836 | 35,033 | (1,231) | (1,570) | 15 | ||
| Operating expenses | (39,500) | (53,292) | (65,852) | (88,265) | (40,039) | (19,926) | ||
| Other undisclosed operating income | 48 | |||||||
| Operating loss: | (11,888) | (44,456) | (30,819) | (89,496) | (41,609) | (19,863) | ||
| Nonoperating income (expense) | (2,834) | (3,054) | (2,756) | 3,744 | 1,350 | 121 | ||
| Other nonoperating income (expense) | (109) | (22) | 255 | 5,140 | 2,287 | |||
| Interest and debt expense | (3,391) | (3,481) | (3,396) | (1,585) | (1,060) | (432) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 3,391 | 3,481 | 3,396 | 1,585 | 1,060 | |||
| Loss from continuing operations before equity method investments, income taxes: | (14,722) | (47,510) | (33,575) | (85,752) | (40,259) | (20,174) | ||
| Other undisclosed income from continuing operations before income taxes | 432 | |||||||
| Loss from continuing operations before income taxes: | (14,722) | (47,510) | (33,575) | (85,752) | (40,259) | (19,742) | ||
| Income tax benefit | 1,698 | 1,443 | 15,455 | |||||
| Loss from continuing operations: | (14,722) | (47,510) | (33,575) | (84,054) | (38,816) | (4,287) | ||
| Loss before gain (loss) on sale of properties: | (14,722) | (47,510) | (33,575) | (84,054) | (38,816) | (4,287) | ||
| Net loss available to common stockholders, diluted: | (14,722) | (47,510) | (33,575) | (84,054) | (38,816) | (4,287) | ||
Comprehensive Income ($ in thousands)
| 3/31/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (14,722) | (47,510) | (33,575) | (84,054) | (38,816) | (4,287) | ||
| Other comprehensive income (loss) | (473) | 2,777 | (542) | (5,170) | (4,150) | |||
| Comprehensive loss, net of tax, attributable to parent: | (15,195) | (44,733) | (34,117) | (89,224) | (42,966) | (4,287) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.